BioCryst Pharmaceuticals’ (BCRX) Outperform Rating Reaffirmed at Royal Bank Of Canada

Royal Bank Of Canada restated their outperform rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report released on Monday,Benzinga reports. They currently have a $13.00 price target on the biotechnology company’s stock.

A number of other equities analysts have also commented on BCRX. Needham & Company LLC reaffirmed a “buy” rating and issued a $17.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, June 25th. Barclays raised their price target on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 7th. Cantor Fitzgerald assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They issued an “overweight” rating and a $20.00 price objective on the stock. Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, Wedbush boosted their target price on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an “outperform” rating in a report on Monday. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $16.89.

BioCryst Pharmaceuticals Stock Down 4.3%

Shares of NASDAQ:BCRX opened at $8.96 on Monday. The firm has a market cap of $1.87 billion, a P/E ratio of -34.46, a P/E/G ratio of 1.87 and a beta of 1.10. BioCryst Pharmaceuticals has a 12-month low of $6.02 and a 12-month high of $11.31. The business has a fifty day simple moving average of $9.98 and a 200 day simple moving average of $8.57.

Institutional Trading of BioCryst Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Lazard Asset Management LLC lifted its position in shares of BioCryst Pharmaceuticals by 68.1% during the 4th quarter. Lazard Asset Management LLC now owns 161,516 shares of the biotechnology company’s stock valued at $1,214,000 after acquiring an additional 65,420 shares during the period. Vanguard Group Inc. increased its stake in BioCryst Pharmaceuticals by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock valued at $164,616,000 after purchasing an additional 1,583,826 shares in the last quarter. Raymond James Financial Inc. bought a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at $80,000. Teacher Retirement System of Texas raised its holdings in shares of BioCryst Pharmaceuticals by 25.1% during the fourth quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company’s stock valued at $438,000 after purchasing an additional 11,711 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 4.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock valued at $14,890,000 after purchasing an additional 91,998 shares during the period. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.